by | Apr 19, 2024 | Uncategorized | 0 comments

Wayne’s Journey

Wayne has lived a rich life that includes his wife, two daughters and three grandkids. He describes himself as someone who “just likes people.” Starting life on a farm, he went on to complete three degrees and teach chemistry in high school, ultimately becoming a principal. Along the way, he owned a grocery store and even carried mail after retirement.

Hearing the news

When he was about 78, Wayne started noticing symptoms including blood in his urine, and went to his local doctor, thinking it was something minor. When he was first told, “you might have a tumor in your bladder,” he became very concerned. Over the next year, he underwent two transurethral resections of bladder tumor (TURBT) procedures, which is usually the first treatment option for non-muscle invasive bladder cancer, and he received injections of Bacillus Calmette-Guérin (BCG) into his bladder. But the BCG alone wasn’t working.

Participating in ImmunityBio’s QUILT 3.032 study

Wayne felt lucky to have a friend tell him about Dr. Sam Chang, a urologist at Vanderbilt University recruiting patients for the QUILT 3.032 study of Anktiva (N-803 and nogapendekin alfa inbakicept-pmln) and BCG in patients like himself who were not cured by BCG alone. From the start of study treatment onward, he says he just got “better and better and better.” He still goes in for check-ups, but according to his physicians, everything looks good.

Indication and Important Safety Information

INDICATION AND USAGE: ANKTIVA is an interleukin-15 (IL-15) receptor agonist indicated with Bacillus Calmette-Guerin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.

WARNINGS AND PRECAUTIONS: Risk of Metastatic Bladder Cancer with Delayed Cystectomy. Delaying cystectomy can lead to the development of muscle invasive or metastatic bladder cancer, which can be lethal. If patients with CIS do not have a complete response to treatment after a second induction course of ANKTIVA with BCG, reconsider cystectomy.

DOSAGE AND ADMINISTRATION: For lntravesical Use Only. Do not administer by subcutaneous or intravenous routes. Instill intravesically only after dilution. Total time from vial puncture to the completion of the intravesical instillation should not exceed 2 hours.

USE IN SPECIFIC POPULATIONS: Pregnancy: May cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception.

ADVERSE REACTIONS: The most common (≥15%) adverse reactions, including laboratory test abnormalities, are increased creatinine, dysuria, hematuria, urinary frequency, micturition urgency, urinary tract infection, increased potassium, musculoskeletal pain, chills and pyrexia.

For more information about ANKTIVA, please see the Full Prescribing Information at www.anktiva.com.

You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch or call 1-800-332-1088. You may also contact lmmunityBio at 1-877-ANKTIVA (1-877-265-8482)

ANKTIVA® is a new choice to help conquer
non-muscle invasive bladder cancer.

For more information, please call 1-877-ANKTIVA

The information contained in this section of the site is intended for U.S. healthcare professionals only. Click “Continue” if you are a healthcare professional.

Visit Patient Site Continue